Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could unlock stroke treatment for thousands

NCT ID NCT03364296

Diagnosis Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether measuring two proteins in the blood (GST-π and PRDX1) can accurately determine if a stroke occurred within the last 4.5 hours. That time window is critical because it determines if patients can receive clot-busting medication. Researchers enrolled 935 adults with stroke symptoms to test this approach. If it works, it could help treat people who wake up with a stroke or don't know exactly when symptoms started.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give doctors a simple blood test to quickly determine when a stroke began, allowing more patients to receive timely clot-busting treatment.
What could go wrong
This is an early diagnostic study, not a treatment trial. The blood markers may not be accurate enough in real-world settings, and results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

935 people

The number who actually took part.

Started

Oct 2018

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients over 18 years old * Patients with symptoms consistent with stroke and a National Institute of Health Stroke Score ≥3 at the inclusion time * Time symptom onset ≤ 24 hours at inclusion: * For patients with time of symptom onset is \<4.5h at inclusion, the time of symptom onset has to be precisely known, with a margin of error not exceeding 30 minutes (through patient or witness interview) * For patients with time of symptom onset is \>4.5h at inclusion, knowledge of precise time of symptom onset is not required. For these patients, to ensure onset-to-inclusion time is between 4.5 and 24 hours at inclusion: * last time patient presented no deficit must be less than 24 hours, * symptoms must have been first recognized more than 4.5 hours before blood draw. * Possibility to perform MRI within the 30 minutes following blood collection * Person affiliated to or beneficiary of a social security plan Exclusion Criteria: * Persons referred in articles L.1121-5, L.1121-7, L.1121-8 and L.1122-2 of the French Public Health Code: Pregnant, parturient or breastfeeding woman ; Minor person (non-emancipated) ; Adult person under legal protection (any form of public guardianship) ; Adult person incapable of giving consent and not under legal protection. * Persons deprived of liberty for judicial or administrative decision. * Persons subject to psychiatric care under articles L.3212-1 and L.3213-1 of the French Public Health Code. * Known cancer in progression. * Known cirrhosis. * Myocardial Infarctions, stroke, Subarachnoid hemorrhage or intracranial injury within 3 months prior to enrolment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stroke, acute

Contacts and locations

Locations

  • Centre Hospitalier de Bar-Le-Duc

    Bar-le-Duc, 55000, France

  • Centre Hospitalier de Troyes

    Troyes, 10003, France

  • Centre Hospitalier de Verdun

    Verdun, 55300, France

  • Fondation Adolphe de Rothschild

    Paris, 75019, France

  • Hôpital Central

    Nancy, 54000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.